Reuters UK

<img alt="" height="1" width="1" />
FDA panel backs expanded use of Merck&#39;s Vytorin
BusinessWeek
Federal health experts are recommending that use of Merck&#39;s blockbuster cholesterol drug Vytorin be expanded to patients with kidney disease, but not those with late-stage disease who are on dialysis. The Food and Drug Administration&#39;s panel of drug ...
FDA Finds No Increased Cancer Risk with VytorinRenal and Urology News
Advisers back Merck drug for some kidney patientsReuters
FDA Panel Says Vytorin Okay for Some Kidney Disease PatientsMedPage Today
Forbes -Bloomberg -Cardiology Today
all 52 news articles &raquo;


More...